First Patient dosed in Phase III insomnia trial
Released
Released
Announcement PDF
ASX Announcement
16 May 2024
First Patient Dosed in Phase III Insomnia Trial
Highlights:
•
•
•
•
Avecho doses first patient in Phase III Clinical Trial testing its oral CBD TPM®-enhanced
soft-gel capsule for insomnia
The trial is the largest sleep study of its kind, targeting 519 patients across sites located in
Melbourne, Sydney, Central Coast, Brisbane, and Perth
The treatment groups will compare nightly CBD doses of 75mg and 150mg CBD with
placebo over an 8-week dosing period
The trial has been designed to suit the requirements of the TGA, FDA and the EMEA, aided
by advice from a number of international sleep experts
Melbourne, Australia, 16 May 2024: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or
the “Company”), focused on developing and commercialising innovative products using its
proprietary Tocopheryl Phosphate Mixture (“TPM®”) drug delivery system, is pleased to announce
that the first patient has been dosed in its Phase III clinical trial (the “Trial”) testing its oral CBD
TPM®-enhanced soft-gel capsule for insomnia.
The trial is the largest of its kind testing cannabidiol and has been designed to suit the requirements
of the Australian Therapeutic Goods Administration (“TGA”), US Food and Drug Agency and the
European Medicines Agency, aided by advice from international sleep and regulatory experts. The
trial target is 519 participants across multiple Australian cities including Melbourne, Sydney,
Brisbane, Central Coast, and Perth. Trial Participants will be randomly assigned to one of three
groups to receive nightly doses of either 75mg or 150mg of CBD, or a placebo for eight weeks.
Participants will use validated questionnaires and daily sleep diaries over the course of the study
to record the duration and quality of their sleep.
A successful Phase III trial is Avecho’s final clinical step in support of a submission to the TGA for
pharmaceutical registration of the CBD TPM soft-gel capsule for the management of insomnia. This
opportunity is particularly significant in Australia, where regulatory changes in 2020 allow for overthe-counter sales of CBD products direct from pharmacy without a prescription, provided they gain
appropriate approvals. Avecho has an opportunity to be the first in this area as no other Phase III
CBD trials in Australia have succeeded.
Insomnia is a sleep disorder defined as dissatisfaction with sleep quantity or quality associated with
difficulty initiating sleep, difficulty maintaining sleep and the inability to return to sleep on
awakening. It can manifest as a primary indication or be symptom of other disorders, including
anxiety and depression. Chronic insomnia is the most prevalent manifestation, characterized by
insomnia symptoms occurring at least three nights per week and for at least three months.
Consequences of insomnia include daytime sleepiness, poor memory function, decline in
concentration with negative impacts on social and work activities. Approximately 30% of the
population in the United States display chronic symptoms. In Australia, as many as 60% of the
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
3440-6518-1734, v. 1
avecho.com.au
population have at least some symptoms of insomnia with a total cost to the Australian economy
estimated to be $19.1 billion1.
National media coverage of the trial in March and April 2024 produced significant public interest,
with over 1600 applicants registering for participation in the study. These initial applicants have
undergone a first round of screening for eligibility, with 135 meeting the strict inclusion criteria for
the study. These patients have now been referred to clinical trial sites to confirm eligibility with
further assessments, and those that remain eligible will commence dosing immediately. The first
patient has now been dosed.
"We are thrilled to commence dosing patients on our pivotal Phase III insomnia trial, marking a
significant milestone not only for Avecho but also for the potential relief of millions suffering from
this debilitating condition", said Dr Paul Gavin, CEO of Avecho Biotechnology.
"This trial is central in our quest to offer the first over-the-counter CBD-based insomnia treatment
in Australia, leveraging Australia’s regulatory changes. Our commitment to rigorous scientific
validation and patient safety is at the core of this effort, and we are optimistic about leading the
way in providing a new, effective option for insomnia sufferers."
Patients interested in participating are invited to visit the clinical trial recruitment portal at
cbdinsomniastudy.com
- ENDS This announcement is authorised for release by the Board of Directors of Avecho Biotechnology Limited.
Questions related to the announcement are welcome via our InvestorHub platform.
Investor + General Enquiries
Dr Paul Gavin
Chief Executive Officer
Avecho Biotechnology Limited
+61 3 9002 5000
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products
using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived
from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and
oral, dermal and transdermal absorption of drugs and nutrients.
Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.
1 Rise and try to shine: The social and economic cost of sleep disorders in Australia, Sleep Health Foundation, Deloitte
Access Economics, April 2021
2
Forward-Looking Statements
Certain statements in this announcement are forward looking statements. Forward-looking statements can
generally be identified by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “intend”,
“plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward-looking statements
speak only as at the date of this announcement. These statements are based on current expectations and
beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that
could cause the actual results, performances and achievements to differ materially from any expected future
results, performance or achievements expressed or implied by such forward looking statements.
No representation, warranty or assurance (express or implied) is given or made by Avecho that the forwardlooking statements contained in this announcement are accurate, complete, reliable or adequate or that they
will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Avecho
and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or
completeness of the forward-looking statements and exclude all liability whatsoever (including negligence)
for any direct or indirect loss or damage which may be suffered by any person as a consequence of any
information in this announcement or any error or omission therefrom.
Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, Avecho disclaims
any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in
these materials to reflect any change in expectations in relation to any forward-looking statements or any
change in events, conditions or circumstances on which any statement is based. Nothing in these materials
shall under any circumstances create an implication that there has been no change in the affairs of Avecho
since the date of the announcement.
Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market, including the recently announced application of TPM® to cannabinoids. The Company
is also developing TPM® to enhance feed efficiency and health of livestock.
See more here - avecho.com.au
3
Share your feedback
Discover